Evidence map›Paper›PMID 33402470›Full record

ArticleIn vivo (Athens, Greece)

Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion

Hironobu Yanagie, Takashi Fujino, Masashi Yanagawa, Toshimitsu Terao, Takashi Imagawa, Mitsuteru Fujihara, Yasuyuki Morishita, Ryouji Mizumachi, Yuuji Murata, Novriana Dewi and 17 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 12 institutions in 1 country.

Hironobu YanagieInstitute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan; h.yanagie@gmail.com.
Takashi FujinoDepartment of Pathology, Saitama Medical University International Medical Center, Hidaka, Japan.
Masashi YanagawaVeterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
Toshimitsu TeraoDepartment of Pharmaceutical Technology, Otsuka Pharmaceutical Factory, Tokushima, Japan.
Takashi ImagawaDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Hyogo, Japan.
Mitsuteru FujiharaSPG Techno Ltd. Co., Miyazaki Techno Research Park, Miyazaki, Japan.
Yasuyuki MorishitaDepartment of Human and Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ryouji MizumachiDepartment of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, Japan.
Yuuji MurataDepartment of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, Japan.
Novriana DewiLaboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Yuuya OnoSPG Techno Ltd. Co., Miyazaki Techno Research Park, Miyazaki, Japan.
Ichiro IkushimaDepartment of Radiology, Miyakonojo Shigun Ishikai Hospital, Miyazaki, Japan.
Koji SeguchiDepartment of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan.
Masashi NagataDepartment of Pharmacy, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Yasumasa NonakaDepartment of Surgery, Keiai-kai Houyou Hospital, Iwate, Japan.
Yoshitaka FuruyaDepartment of Surgery, Sodegaura Satukidai Hospital, Chiba, Japan.
Tomoyuki HisaTokyo Bunkyo Study Center, The Open University of Japan, Tokyo, Japan.
Takeshi NagasakiDepartment of Bioengineering, Osaka City University Graduate school of Engineering, Osaka, Japan.
Kazuhiko ArimoriDepartment of Pharmacy, Miyazaki Medical University Hospital, Miyazaki, Japan.
Tadao NakashimaKyushu Medical Resource Foundation, Miyazaki, Japan.
Takumichi SugiharaLaboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Kazuhiro KakimiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Minoru OnoCooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Jun NakajimaCooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Masazumi EriguchiDepartment of Surgery, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Shushi HigashiKyushu Medical Resource Foundation, Miyazaki, Japan.
Hiroyuki TakahashiInstitute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan.
Niigata University of Pharmacy and Applied Life Sciences · JPUniversity of Tokyo Hospital · JPThe University of Tokyo · JPJapan Anti Tuberculosis Association · JPKobe University · JPOsaka City University · JPOtsuka (Japan) · JPSaitama Medical University · JPThe Open University of Japan · JPTokyo Medical and Dental University Hospital · JPUniversity of Miyazaki Hospital · JPVeterinary Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimA mixture of anticancer agents and iodized poppy seed oil (IPSO) has been widely used for intra-arterial chemotherapy of hepatocellular carcinoma. However, the anticancer agents can easily separate from IPSO, so the therapeutic potential is limited. We developed epirubicin-entrapped water-in-oil-in-water emulsion (WOW-Epi) using a double-membrane emulsification technique. MATERIALS AND

methodsWe delivered WOW-Epi through a hepatic arterial injection to VX2 hepatic tumor rabbit model (1.2 mg/kg).

resultsVX2 tumor growth was selectively suppressed in the WOW-Epi-treated group compared with the control treated groups. The accumulation of WOW in nearby cancer cells was confirmed via electron-microscopy. Endocytosis seemed to be the mechanism underlying the uptake of WOW.

conclusionWOW-Epi led to tumour growth suppression in vivo. WOW does not cause toxicity to arterial vessels. WOW-Epi will be hopefully used for repeated intra-arterial chemotherapy to HCC patients in the near future.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsEmulsionsEpirubicinHumansRabbitsWaterEmulsionsEpirubicinWaterepirubicinhepatocellular carcinomaintra-arterial chemotherapyWater-in-oil-in-water emulsion

Identifiers

PMID33402470
PMCPMC7880746
OpenAlexW3118867721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.